RVL Pharmaceuticals

RVL Pharmaceuticals Current Liabilities

The Current Liabilities of RVL Pharmaceuticals (RVLPQ) as of Nov 16, 2026 is 33.06 M USD. In the previous year, Current Liabilities was 36.24 M USD — a change of -8.79% (lower).

Current Liabilities

33.06 MUSD

YoY

-8.79%

Last updated:

Current Liabilities of RVL Pharmaceuticals is 2022 33.06 M USD. Current Liabilities of RVL Pharmaceuticals was 2021 36.24 M USD. It decreases by -8.79% lower compared to the previous year.

The RVL Pharmaceuticals Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2016
186.93 M USD
Jan 1, 2017
212.45 M USD
Jan 1, 2018
201.81 M USD
Jan 1, 2019
142.54 M USD
Jan 1, 2020
104.45 M USD
Jan 1, 2021
36.24 M USD
Jan 1, 2022
33.06 M USD
The RVL Pharmaceuticals Current Liabilities history
YEARCurrent LiabilitiesYoY
33.06 MUSD-8.79%
36.24 MUSD-65.31%
104.45 MUSD-26.72%
142.54 MUSD-29.37%
201.81 MUSD-5.01%
212.45 MUSD+13.65%
186.93 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RVL Pharmaceuticals Stock analysis

What does RVL Pharmaceuticals do? Osmotica Pharmaceuticals PLC is a global pharmaceutical company based in Dublin, Ireland. It was founded in 2008 and focuses on the development and marketing of specialized pharmaceutical products for the treatment of neurological and psychiatric disorders, as well as behavioral disorders. The company is divided into three business segments: the Commercial Part, the Branded Part, and the Trident Part. The Commercial Part is responsible for marketing generic pharmaceuticals and other specialty products in the USA and Canada. This includes products such as Venlafaxine ER for the treatment of depression and the Parkinson's medication Apomorphine. The Branded Part is responsible for the development and marketing of its own products. This includes products such as Osmolex ER for the treatment of Parkinson's and akathisia, as well as Ontinua ER for the treatment of fibromyalgia and neuropathies. The Trident Part of the company focuses on the development of novel ophthalmology products and other specialty products for the global market. The company has a strong commitment to clinical research and development, particularly in the development of new products for use in neurology and psychiatry. Osmotica holds a number of patents for its products and has a range of products in various stages of clinical development. The success of Osmotica is based on its business model, which relies on ongoing innovation through research and development, as well as a strong distribution network for its products. Thanks to its broad product portfolio and global presence, the company is well positioned for further growth and the expansion into new markets in the future. Overall, Osmotica Pharmaceuticals PLC is an emerging pharmaceutical company with a strong focus on the development of specialized products for neurological and psychiatric disorders, as well as behavioral disorders. The company has a broad product portfolio and is well positioned for future growth. RVL Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RVL Pharmaceuticals stock

Current Liabilities of RVL Pharmaceuticals is 33.06 M USD in 2022.

Current Liabilities of RVL Pharmaceuticals changed from 36.24 M USD to 33.06 M USD, representing a -8.79% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities RVL Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's RVL Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — RVL Pharmaceuticals

All Key Metrics — RVL Pharmaceuticals